Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00979212 · ClinicalTrials.gov registry record · Phase 2

Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer

A Phase 2 study of Lung Cancer, sponsored by Radiation Therapy Oncology Group.

Completed
Registry status
Phase 2
Development phase
71
Enrollment target
20
Study locations

NCT00979212: Completed Phase 2 study of Lung Cancer, sponsored by Radiation Therapy Oncology Group.

NCT00979212 is a Phase 2 study of Lung Cancer that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 71 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00979212, a Phase 2 study of Lung Cancer, has completed, sponsored by Radiation Therapy Oncology Group.

COMPLETED
Registry status
Phase 2
Development phase
71 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy (CT), such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy (RT) uses high-energy x-rays to kill tumor cells. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving these treatments before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known whether chemotherapy and radiation therapy are more effective when given with or without panitumumab in treating patients with non-small cell lung cancer. PURPOSE: This randomized phase II trial is studying chemotherapy and radiation therapy to see how well they work when given with or without panitumumab in treating patients with stage IIIA non-small cell lung cancer.

Primary Outcome

The assessment of whether mediastinal nodes which were involved at the time of study registration were clear of disease following induction chemoradiotherapy with or without panitumumab; the assessment is made at the time of surgery 4-6 weeks after chemoradiation. If surgery could not be performed, the patient was considered as not having had mediastinal nodal clearance.

Conditions Studied

Lung Cancer

Interventions

  • DRUG carboplatin
  • DRUG panitumumab
  • DRUG paclitaxel
  • PROCEDURE surgery

Study Locations (20)

Maryland

  • Greenebaum Cancer Center at University of Maryland Medical Center - Baltimore
  • St. Agnes Hospital Cancer Center - Baltimore
  • Cancer Institute at St. Joseph Medical Center - Towson

Ohio

  • Summa Center for Cancer Care at Akron City Hospital - Akron
  • Charles M. Barrett Cancer Center at University Hospital - Cincinnati
  • Cleveland Clinic Taussig Cancer Center - Cleveland

California

  • Mercy Cancer Center at Mercy San Juan Medical Center - Carmichael
  • Radiological Associates of Sacramento Medical Group, Incorporated - Sacramento

Minnesota

  • Fairview Southdale Hospital - Edina
  • Virginia Piper Cancer Institute at Abbott - Northwestern Hospital - Minneapolis

New York

  • NYU Cancer Institute at New York University Medical Center - New York
  • James P. Wilmot Cancer Center at University of Rochester Medical Center - Rochester

Colorado

  • Penrose Cancer Center at Penrose Hospital - Colorado Springs

Kentucky

  • Lucille P. Markey Cancer Center at University of Kentucky - Lexington

Louisiana

  • CCOP - Ochsner - New Orleans

Trial Details

FieldValue
Enrollment Target 71 participants
Start Date 2011-02
Est. Completion 2022-05-20
Phase Phase 2
Radiation Therapy Oncology Group

144 total trials

What the finished NCT00979212 record still lists

NCT00979212 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which carboplatin is the first listed.

NCT00979212 names 20 study sites across 13 states, led by Maryland, Ohio, California.

Frequently Asked Questions

What is clinical trial NCT00979212 about?

NCT00979212 is a clinical study titled "Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy (CT), such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy (RT) uses high-energy x-rays to kill tumor cells. Monoclonal antibodies, such as ...

What is the current status of trial NCT00979212?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 71 participants. The study started on 2011-02. Estimated completion is 2022-05-20.

What conditions does trial NCT00979212 study?

This clinical trial studies the following conditions: Lung Cancer.

What interventions are being tested in trial NCT00979212?

The interventions under investigation include: carboplatin (DRUG), panitumumab (DRUG), paclitaxel (DRUG), surgery (PROCEDURE).

Who is sponsoring clinical trial NCT00979212?

This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00979212 being conducted?

This trial has 20 study locations across California, Colorado, Kentucky, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00979212's enrollment target sits among peer trials

71 223rd of 409 higher than 187 of 409 other Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05452889 · 71 participants · Early Phase 1

    PET Image in PAH Patients

  • NCT05766943 · 71 participants · NA

    Reduction of Myopotential Interference With Smart Pass in S-ICD Patients

  • NCT06229678 · 71 participants · Early Phase 1

    Ketones, SGLT2, HFrEF

  • NCT06377566 · 71 participants · Phase 2

    A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00979212, the US trial registry maintained by the National Library of Medicine. NCT00979212 (small enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.